HIV Negative and HIV Prevention

CID 0702 Apheresis procedures to obtain leukocytes from HIV negative subjects

Q:            Samples used as a negative control for exploring new methods of activating resting HIV infected cells in laboratory

POP:        must be HIV negative and > 18 years of age

DUR:        up to 3 years          

CALL:      Amanda Crooks 919-843-9564

HVTN 704/HPTN 085: A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection

Q:            To evaluate the safety and tolerability of VRC01 monocolonal antibody (mAb) administered through IV infusion; determine if the VRC01 mAb prevents HIV-1    infection; and to estimate the level of efficacy. 

POP:        HIV–uninfected 18 to 50 year old men and transgender individuals who have sex with men

MED:        VRC01 human monoclonal antibody (mAb)

DUR:        Approximately 22 months with monthly visits

CALL:      Chris Evans, ANP-BC 919.843.8759, or Alex Delaney, 919-966-8353